Evolution of tumors, and evolution generally, occurs by variation and selection. Variation creates the ability to evolve (evolvability). Whereas conventional therapies kill cells or stop them from growing (are anti- proliferative), proposed novel interventions that would inhibit the ability to evolve promise new and fundamentally different ways to inhibit oncogenesis and thwart resistance. The Cancer Evolvability Program (CE) aims to understand the fundamental underlying molecular mechanisms that generate variation and so drive tumor evolution; to develop new molecular approaches and tools to advance cancer diagnosis and therapy; and to develop with other CCSG programs the conceptual and technical frameworks for translational cancer research. The CE Program encompasses two themes, which focus on the two basic routes that generate variation: (1) Intrinsic: Genome and Phenotypic Plasticity (mutation, genome rearrangement, recombination, epigenetic and stochastic protein and RNA variation); and (2) Extrinsic: Infectious Oncogenesis and Microbiome, in which introduction of foreign genes, proteins, RNAs, and other molecules and genetic programs by infectious agents (viruses, microbes, microbiome) promote (or prevent) oncogenesis. The CCSG supports this research program by providing key shared resources, particularly Cytometry and Cell Sorting, Integrated Microscopy, Genomic and RNA Profiling, and Proteomics; as well as administrative support for meetings, clubs and interest groups, and pilot funding and recruitment funds. The CE Program currently has 31 members from ten departments in two institutions. Thirty members have primary appointments at Baylor College of Medicine, one member has a primary appointment at the University of Texas and therefore is an adjunct member. The Cancer Evolvability Program currently has $9.6M in peer-reviewed funding (direct costs per annum), $2.6M from NCI and $1.5M in other peer reviewed funding mostly from the Cancer Prevention and Research Initiative of Texas (CPRIT). Most of this is in the form of R01 grants. Members of the Cancer Evolvability Program published a total of 452 cancer-related papers in the previous funding period: 28% were inter-programmatic, 13% were intra-programmatic, and 50% were ?inter-institutional? (collaborations outside the Dan L Duncan Cancer Center).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-12
Application #
9525818
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
12
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Creighton, Chad J (2018) The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Rev Anticancer Ther 18:973-980
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Byrd, Tiara T; Fousek, Kristen; Pignata, Antonella et al. (2018) TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res 78:489-500
Xing, Zhen; Zhang, Yanyan; Liang, Ke et al. (2018) Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res 78:4524-4532
Chiang, Angie C A; Fowler, Stephanie W; Savjani, Ricky R et al. (2018) Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med 215:1349-1364
Szwarc, Maria M; Hai, Lan; Gibbons, William E et al. (2018) Retinoid signaling controlled by SRC-2 in decidualization revealed by transcriptomics Reproduction 156:387-395
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240
Kho, Jordan; Tian, Xiaoyu; Wong, Wing-Tak et al. (2018) Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. Am J Hum Genet 103:276-287
Liu, Yanhong; O'Brien, Jacqueline L; Ajami, Nadim J et al. (2018) Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res 8:1775-1787
Scavuzzo, Marissa A; Hill, Matthew C; Chmielowiec, Jolanta et al. (2018) Endocrine lineage biases arise in temporally distinct endocrine progenitors during pancreatic morphogenesis. Nat Commun 9:3356

Showing the most recent 10 out of 991 publications